Compare iShares MSCI South Africa ETF (EZA) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Africa ETF vs Gilead Sciences, Inc. — how do they compare? iShares MSCI South Africa ETF trades at $62.78, while Gilead Sciences, Inc. trades at $135.56 (market cap $163.51B). The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while iShares MSCI South Africa ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, iShares MSCI South Africa ETF nearer its low. Which is the better fit depends on your goals.
| EZA | GILD | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $81.60 | $155.80 |
52-Week Low | $53.05 | $108.22 |
Market Cap | — | $163.51B |
Enterprise Value | — | $178.05B |
Dividend Yield | — | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EZA is trading at $62.83, down 0.98% on the day, with a bearish technical outlook indicated by moving averages and overall momentum. The stock shows neutral oscillator readings but faces selling pressure according to ADX indicators. Recent corporate actions include a $1.43 dividend scheduled for June 2026, providing some income appeal despite current technical weakness.
The stock faces headwinds from bearish technical signals while lacking current fundamental data for comprehensive analysis. Investment opportunity exists through the upcoming dividend, but requires monitoring of earnings reports and financial metrics once available. Key risks include market volatility and the need for updated financial disclosures to assess true valuation.
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI South Africa ETF
EZA is a country-specific ETF that tracks the South African equity market. It provides exposure to large and mid-cap companies across key sectors like materials and financials, with top holdings such as AngloGold Ashanti and Naspers.
Read more on EZA →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
